Cancer Monoclonal Antibodies Market, $106.8 Billion by 2031: Report

The rise in incidence of cancer, an increase in the number of medication approvals, advancements in technology leading to improved and efficient testing methods, an increase in investment in R&D of cancer monoclonal antibodies, and the increase in demand for personalized medicines drive the growth of the global cancer monoclonal antibodies market. Region-wise, Asia-Pacific is likely to dominate in terms of revenue in 2031.


Portland, OR, March 20, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global cancer monoclonal antibodies market generated $55.6 billion in 2021, and is estimated to reach $106.8 billion by 2031, witnessing a CAGR of 7% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.

Download a Free Sample Copy of the Report- https://www.alliedmarketresearch.com/request-sample/32341

Report coverage & details:

Report Coverage Details
Forecast Period 2022–2031
Base Year 2021
Market Size in 2021 $55.6 Billion
Market Size in 2031 $106.8 Billion
CAGR 7%
No. of Pages in Report 300
Segments Covered Antibody Type, Application, End User and Region
  The rise in incidence of cancer
An increase in the number of medication approvals
Advancements in technology leading to improved and efficient testing methods
An increase in investment in R&D of cancer monoclonal antibodies
The increase in demand for personalized medicines
Opportunities The rise of immunotherapy, which uses monoclonal antibodies to treat cancer
Restraints A lack of skilled professionals to carry out therapy

Impact of COVID-19 Pandemic on Cancer Monoclonal Antibodies Market:

  • The outbreak of the COVID-19 pandemic had a negative impact on the cancer monoclonal antibodies market as the hospitalization rate for infected patients increased and the scope of hospitalization for patients for surgeries reduced significantly.
  • Due to the increase in hospitalization of Covid-19 patients, healthcare professionals postponed cancer treatments as patients with cancer have low immunity and there are high chances that they may catch infection quickly. Hence, the focus shifted to the management and control of the COVID-19 patients. Therefore, there was a reduction in cancer diagnosis cases during the pandemic, leading to a decline in demand for cancer monoclonal antibody testing.
  • The market has gained momentum with life getting back to normal. 

Procure Complete Report (300 Pages PDF with Insights, Charts, Tables, and Figures)
https://www.alliedmarketresearch.com/checkout-final/cancer-monoclonal-antibodies-market

The report offers a detailed segmentation of the global cancer monoclonal antibodies market based on antibody type, application, end user, and region. The report provides an analysis of each segment and sub-segment with the help of tables and figures. This analysis helps market players, investors, and new entrants in determining the sub-segments to be tapped on to achieve growth in the coming years.

In terms of antibody type, the humanized segment captured the largest market share of two-fifths of the global cancer monoclonal antibodies market in 2021 and is expected to maintain a prominent revenue growth in 2031. The same segment is expected to achieve the fastest CAGR of 7.1% through 2031. The report also discusses the murine and chimeric segments.

In terms of application, the blood cancer segment captured the largest market share of more than one-third of the global cancer monoclonal antibodies market in 2021 and is likely to dominate the market in 2031. However, the lung cancer segment is expected to dominate in terms of revenue and achieve the fastest CAGR of 7.3% through 2031. The report also offers an analysis of breast cancer and others segments.

For Purchase Inquiry- https://www.alliedmarketresearch.com/purchase-enquiry/32341

Based on end user, the hospitals and clinics segment held the largest share in 2021, accounting for nearly three-fourths of the global cancer monoclonal antibodies market and would maintain its dominance through 2031. Moreover, the same segment is estimated to witness the fastest CAGR of 7.1% during the forecast period. The study also includes an analysis of the research and academic institute/laboratories segment.

Based on region, the market in North America was the largest in 2021, accounting for more than two-fifths of the global cancer monoclonal antibodies market in 2021 and is expected to rule the roost during the forecast period. However, the market in Asia-Pacific is expected to manifest the highest CAGR of 7.5% from 2022 to 2031. The other regions analyzed in the study include LAMEA and Europe.

Leading players of the global cancer monoclonal antibodies market analyzed in the research include,

  • Roche Holdings Ltd.
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca plc
  • Merck & Co. Inc.
  • Celgene Limited
  • Bistrol-Myers Squibb
  • Eli Lilly & Co.
  • Abbvie Inc.

The report analyzes these key players of the global cancer monoclonal antibodies market. These players have adopted various strategies such as expansion, new product launches, partnerships, and others to increase their market penetration and strengthen their position in the industry. The report is helpful in determining the business performance, operating segments, product portfolio, and developments by every market player.

Trending Reports in Healthcare Industry:

Laser Hair Removal Market – Global Opportunity Analysis and Industry Forecast, 2022–2031

Healthcare Staffing Market- Global Opportunity Analysis and Industry Forecast, 2022–2031

Lab Information Management System Market - Global Opportunity Analysis and Industry Forecast, 2022–2031

Ambulance Services Market- Global Opportunity Analysis and Industry Forecast, 20222–2031

Endometriosis Market - Global Opportunity Analysis and Industry Forecast, 2022–2031

                                                                                 
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model):

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms the utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high-quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com 
Web: https://www.alliedmarketresearch.com